229 related articles for article (PubMed ID: 31559475)
1. Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Tanaka N; Takeda T; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
World J Urol; 2020 Jul; 38(7):1749-1756. PubMed ID: 31559475
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
[TBL] [Abstract][Full Text] [Related]
3. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy.
Saito T; Matsumoto K; Kosaka T; Yasumizu Y; Tanaka N; Takeda T; Morita S; Mizuno R; Asanuma H; Oya M
Int J Clin Oncol; 2023 May; 28(5):707-715. PubMed ID: 36929093
[TBL] [Abstract][Full Text] [Related]
4. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
[TBL] [Abstract][Full Text] [Related]
5. Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.
Matsumoto K; Mizuno R; Tanaka N; Ide H; Hasegawa M; Ishida M; Hayakawa N; Yasumizu Y; Hagiwara M; Hara S; Kikuchi E; Miyajima A; Nakagawa K; Nakajima Y; Nakamura S; Nakashima J; Oya M
Med Oncol; 2014 Jul; 31(7):45. PubMed ID: 24913809
[TBL] [Abstract][Full Text] [Related]
6. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy.
Komori T; Matsumoto K; Kosaka T; Takeda T; Kamitani R; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Asanuma H; Oya M
Ann Surg Oncol; 2023 Oct; 30(11):6936-6942. PubMed ID: 37418130
[TBL] [Abstract][Full Text] [Related]
8. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
9. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
[TBL] [Abstract][Full Text] [Related]
10. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.
Taguchi S; Fukuhara H; Azuma T; Suzuki M; Fujimura T; Nakagawa T; Ishikawa A; Kume H; Igawa Y; Homma Y
BMC Urol; 2014 Oct; 14():81. PubMed ID: 25323845
[TBL] [Abstract][Full Text] [Related]
11. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
12. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
13. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
14. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
15. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.
Choo R; Hruby G; Hong J; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):269-76. PubMed ID: 12023129
[TBL] [Abstract][Full Text] [Related]
16. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
17. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
[TBL] [Abstract][Full Text] [Related]
19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.
Nair SM; Peters M; Kurver P; Lavi A; Verhoeff JJC; van der Voort van Zyp JRN; van Son MJ; Chin JL
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):186-192. PubMed ID: 32814843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]